NOV 17, 202655 MINS READ
Creatine phosphate (N-phosphorylcreatine, CAS 67-07-2) is the phosphorylated derivative of creatine (N-methyl-N-guanylglycine), bearing a high-energy phosphate bond at the guanidino nitrogen. Its molecular formula is C₄H₁₀N₃O₅P, with a molecular weight of approximately 211.11 g/mol (anhydrous form). The compound exists predominantly as disodium or tetrasodium salts in pharmaceutical formulations to enhance aqueous solubility and stability 1. The reversible enzymatic reaction catalyzed by creatine kinase (CK) is central to cellular bioenergetics: PCr + ADP + H⁺ ⇌ ATP + Cr. This reaction maintains high ATP/ADP ratios in tissues with fluctuating energy demands, such as myocardium, brain, and skeletal muscle 2. When evaluating a Creatine Phosphate Supplier, understanding the salt form (e.g., disodium tetrahydrate vs. anhydrous disodium) is critical, as hydration state directly impacts molecular weight, hygroscopicity, and dosing accuracy 4.
Key physicochemical properties relevant to supplier specifications include:
Suppliers must provide Certificates of Analysis (CoA) documenting these parameters via validated HPLC-ELSD or HPLC-UV methods (see Quality Control section) 89.
The choice of synthetic route profoundly influences product purity, cost, and environmental footprint. Two primary methods dominate industrial production:
This classical approach, first reported by Zeile and Fawaz (1938) and refined by Ennor and Stocken (1948), involves direct phosphorylation of creatine in strongly alkaline media (pH >12) using POCl₃ 511. The reaction proceeds via formation of dichlorophosphoric acid creatinine intermediate, followed by hydrolysis and neutralization with NaOH to yield disodium creatine phosphate 10. Key process parameters include:
Advantages: High yield (60–75% based on creatine); scalable to multi-kilogram batches 10.
Disadvantages: Use of hazardous POCl₃ (corrosive, moisture-sensitive) necessitates specialized equipment and waste treatment; residual phosphate impurities (0.3–0.8%) require ion-exchange chromatography for pharmaceutical-grade material 610.
Recent innovations include continuous-flow microreactor synthesis, which reduces POCl₃ residence time and improves safety while achieving >70% yield and <0.2% phosphate residue 10.
This biocatalytic route, developed by Beaucamp (1972), employs aqueous muscle extract containing creatine kinase, phosphoglycerate kinase, and glyceraldehyde-3-phosphate dehydrogenase to transfer phosphate from 3-PGA to creatine in the presence of catalytic ATP 5. The process operates at pH 8.5–9.0 and 25–37°C, followed by brief heating (70–100°C, 5–10 min) to denature enzymes and facilitate product recovery 5.
Advantages: Mild conditions; no toxic reagents; high stereochemical purity; suitable for GMP-compliant facilities 5.
Disadvantages: Lower volumetric productivity (10–20 g/L vs. 50–100 g/L for chemical route); enzyme cost (~$500/kg 3-PGA vs. $50/kg POCl₃); requires cold-chain logistics for enzyme stability 5.
Suppliers utilizing enzymatic synthesis typically target high-value applications (e.g., injectable cardioprotectants) where purity and regulatory acceptance justify premium pricing 5.
Regardless of synthetic route, crude creatine phosphate undergoes purification via:
Suppliers should disclose purification protocols and provide impurity profiles (HPLC chromatograms) to verify absence of genotoxic impurities (e.g., POCl₃ hydrolysis products) 89.
Robust analytical methods are essential for supplier qualification and batch release. Regulatory agencies (FDA, EMA, NMPA) mandate validated assays per ICH Q2(R1) guidelines.
HPLC-ELSD (Evaporative Light Scattering Detection): Preferred for simultaneous quantitation of creatine phosphate, creatine, creatinine, and inorganic phosphate 8. Typical conditions:
HPLC-UV: Alternative method using UV detection at 210 nm for creatine phosphate (ε = 1,200 M⁻¹cm⁻¹) and 234 nm for creatinine 9. Advantages include lower equipment cost; disadvantages include interference from UV-absorbing excipients 9.
Suppliers must demonstrate stability via forced degradation studies (acid, base, oxidative, thermal, photolytic stress per ICH Q1A/Q1B) 9. Validated methods should resolve degradation products (e.g., creatine, creatinine, cyclic creatine phosphate) with resolution >2.0 9. Acceptance criteria: ≥95.0% assay after 6 months at 25°C/60% RH (Zone II) or 3 months at 40°C/75% RH (accelerated) 9.
Suppliers should provide multi-batch CoAs (n ≥3) demonstrating consistent compliance with these specifications.
Sourcing from GMP-certified suppliers is non-negotiable for pharmaceutical applications. Key regulatory considerations include:
Suppliers should hold an active Type II DMF (US FDA) or CEP (EDQM) for creatine phosphate disodium, documenting manufacturing site, process validation, impurity control strategy, and stability data 4. DMF holders must update filings within 30 days of process changes 4.
Facilities must demonstrate:
While creatine phosphate lacks a USP monograph, suppliers may reference:
Suppliers targeting EU markets should align specifications with Ph. Eur. requirements for related substances (individual impurity <0.5%, total <2.0%) 8.
Creatine phosphate is approved in >30 countries (China, Russia, Italy, Japan) as an injectable cardioprotectant for acute myocardial infarction, heart failure, and cardiac surgery 23. Mechanism: PCr donates phosphate to ADP in ischemic myocardium, sustaining ATP levels and reducing infarct size 2. Clinical dosing: 1–2 g IV bolus followed by 1 g q12h for 5–7 days 2.
Supplier requirements: Sterile, pyrogen-free API (<0.5 EU/mg); particle size <50 μm for lyophilized vials; stability ≥24 months at 2–8°C 4. Suppliers must provide stability data in final formulation (e.g., 1 g/10 mL in 0.9% NaCl) demonstrating <5% degradation over 48 h at 25°C 13.
Preclinical studies demonstrate PCr efficacy in Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) models, attributed to enhanced mitochondrial function and reduced oxidative stress 17. Oral bioavailability is limited (<10%) due to intestinal hydrolysis; prodrug strategies (e.g., salicyl alcohol esters, cyclocreatine phosphate) improve membrane permeability 1516.
Supplier requirements: Research-grade PCr (≥95% purity) for in vitro studies; GMP-grade for IND-enabling toxicology; prodrug synthesis capabilities (esterification, salt formation) 1516.
Creatine phosphate supplements (typically as disodium salt) are marketed for ATP replenishment during high-intensity exercise 112. Enteric-coated formulations bypass gastric degradation, enhancing bioavailability vs. creatine monohydrate 12.
Supplier requirements: Food-grade PCr (≥98% purity, compliant with FDA GRAS or EU Novel Foods Regulation); kosher/halal certification; non-GMO documentation 112. Stability in acidic beverages (pH 3.0–4.5) is critical; formulations with tribasic potassium phosphate buffer (pH 7.2–7.8) maintain >90% PCr over 6 months at 25°C 1319.
Creatine phosphate supplementation of organ preservation solutions (e.g., University of Wisconsin solution) improves post-transplant graft function by maintaining ATP during cold ischemia 2. Dosing: 5–10 mM PCr in preservation medium 2.
Supplier requirements: Ultra-pure PCr (≥99.5%, endotoxin <0.1 EU/mg); compatibility with hypothermic storage (4°C, 48–72 h); sterile filtration (0.22 μm) 2.
Selecting a Creatine Phosphate Supplier requires systematic evaluation across technical, regulatory, and commercial dimensions. Recommended qualification workflow:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| BOEHRINGER MANNHEIM GMBH. | Pharmaceutical-grade creatine phosphate manufacturing for injectable cardioprotectants and research applications requiring high purity and GMP compliance. | Enzymatic Creatine Phosphate Production System | Enzymatic phosphorylation using 3-phosphoglyceric acid and muscle extract achieves excellent yields without toxic reagents like phosphorus oxychloride, enabling simple and economically feasible large-scale production. |
| SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD. | Quality control and batch release testing for creatine phosphate disodium salt intermediates and finished pharmaceutical products in GMP-certified facilities. | HPLC-ELSD Quality Control Method | High-performance liquid chromatography with evaporative light scattering detection enables simultaneous quantitation of creatine phosphate, creatine, creatinine, and inorganic phosphate with LOQ of 0.05% for impurities, ensuring pharmaceutical-grade purity ≥98%. |
| XENOPORT INC. | Treatment of ischemia, heart failure, neurodegenerative diseases (Huntington's, Parkinson's, ALS), and tissue preservation for organ transplantation requiring enhanced cellular ATP levels. | Membrane Permeable Creatine Phosphate Prodrugs | Salicyl alcohol ester and cyclocreatine phosphate prodrugs improve membrane permeability and oral bioavailability (>10-fold vs. native creatine phosphate), enhancing therapeutic efficacy in energy metabolism disorders. |
| HARBIN BOLAI PHARMACEUTICAL CO. LTD. | Oral solid dosage forms for cardiovascular therapeutics, sports nutrition, and muscle performance enhancement where injectable routes are impractical or patient compliance is challenging. | Enteric-Coated Oral Creatine Phosphate Formulation | Enteric coating with acrylic resin II protects creatine phosphate sodium from gastric degradation, achieving >90% stability over 6 months and enabling oral administration for cardiac and skeletal muscle protection. |
| THE COCA-COLA COMPANY | Sports nutrition and ergogenic supplement beverages for ATP replenishment during high-intensity exercise, providing convenient alternative to powdered creatine monohydrate supplements. | Stable Ready-to-Drink Creatine Beverage | Buffering system with tribasic potassium phosphate maintains pH 7.2-7.8, achieving <5% creatine degradation over 6 months at 25°C and enabling shelf-stable liquid creatine supplementation. |